Study to investigate the safety profile of AZD4721 after single doses at different dose levels

Study identifier:D5200C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Single-blind, Randomised, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AZD4721 Solution After Single Ascending Doses, and to Compare the Oral Bioavailability of Single Doses of Solution and Suspension in Healthy Subjects

Medical condition

Safety,plasma AUC and Cmax, plasma AUC 0-t, t1/2λz, and tmax

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4721 Solution, AZD4721 Placebo, AZD4721 Suspension

Sex

All

Actual Enrollment

44

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Jul 2013
Primary Completion Date: 01 Dec 2013
Study Completion Date: 01 Dec 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria